Association of Amisulpride Response in Schizophrenia With Brain Image

Launched by CHA UNIVERSITY · Mar 24, 2014

Keywords

ClinConnect Summary

1. Study rationale 1-1.

* Predicting the treatment response of antipsychotic drug in schizophrenia patients has been an issue in psychiatry. However, it is not clear if the findings of structural magnetic resonance imaging (MRI) such as brain gray matter volumes and white matter connectivities, are related to the treatment response of antipsychotic drugs.
* The cognitive and behavioural symptoms of patients with schizophrenia are hypothesized to involve a disruption of neuronal interactions resulting in dysfunctional cognitive integration (Friston et al., 1995, 1996). This hypothesis...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • between 21 and 60 years of age
• • diagnosed with schizophrenia, based on the Structured Clinical Interview for DSM-IV(SCID)
• • first or second episode of schizophrenia patient
• • the presence of positive or negative symptoms or both, resulting in illness of at least mild severity (≥3 on the Clinical Global Impression (CGI) severity scale
• Exclusion Criteria:
• • evidence of organic mental disorder or mental retardation
• • severe drug or alcohol dependence that required inpatient treatment and/or detoxification
• • other conditions, such as a serious medical condition, a history of bipolar or schizoaffective disorder, suicidality, possibility of pregnancy, lactation, or inability/unwillingness to use contraception
• • contraindicated with Solian® by the product label